Cell-free tissue replacement for tissue engineering
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61L-027/36
A61L-027/38
출원번호
US-0274156
(2014-05-09)
등록번호
US-9597429
(2017-03-21)
발명자
/ 주소
Schmidt, Christine E.
Hudson, Terry
출원인 / 주소
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
대리인 / 주소
Flores, Edwin S.
인용정보
피인용 횟수 :
0인용 특허 :
29
초록▼
The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solution
The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess detergent. The natural, cell-free tissue replacement may be a nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and/or is immunologically tolerated. Other forms of the invention are a composition and kit prepared by the method of making a native, cell-free tissue replacement. The present invention may be modified for use in diagnostic, therapeutic, and prophylactic applications.
대표청구항▼
1. A method for preparing a native, nerve cell-free tissue replacement nerve graft comprising the steps of: soaking the nerve graft for at least six hours in a solution comprising sulfobetaine;washing the nerve graft in one or more solutions of a buffered salt;extracting the nerve graft in a mixture
1. A method for preparing a native, nerve cell-free tissue replacement nerve graft comprising the steps of: soaking the nerve graft for at least six hours in a solution comprising sulfobetaine;washing the nerve graft in one or more solutions of a buffered salt;extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent; andwashing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the nerve graft is immunologically tolerated when implanted. 2. The method of claim 1, further comprising the step of: adhering one or more components to the nerve graft before storing, wherein the components are selected from the group consisting of a cell, a polymer, a bioactive compound, and combinations thereof. 3. The method of claim 2, wherein the cells are obtained from a donor, a host, from cell culture from a donor or a host, or cell cultures of established cells, tissue cells, or transformed cell lines. 4. The method of claim 2, wherein the bioactive compound is selected from the group consisting of a drug, protein, peptide, polysaccharide, fatty acid, nucleic acid, oligonucleotide, detectable agent, organic molecules, inorganic molecules or salts and combinations thereof that include natural or synthetic analogs, derivatives, or mimetic versions of the bioactive compound for therapeutic, prophylactic and diagnostic purposes. 5. The method of claim 2, wherein the polymer is selected from the group consisting of naturally occurring, synthetically-derived, covalently crosslinkable, ionically crosslinkable, hydrophilic, and combinations thereof. 6. The method of claim 1, wherein the nerve graft is further modified into a structure selected from the group consisting of a suture, tube, sheet, film, scaffold, valve, limb replacement, tissue transplant, and joint for delivery into the body. 7. The method of claim 1, wherein the step of washing the nerve graft tissue replacement comprises serial solutions of a buffered salt comprises three serial washes of 100 mM sodium and 50 mM phosphate for about 15 minutes each. 8. The method of claim 1, wherein the nerve graft is harvested from mammalian cadaver. 9. The method of claim 8, wherein the nerve graft is cleaned of fat and blood after harvesting and rinsed for several hours in deionized distilled water. 10. A native, neural cell-free tissue replacement nerve graft made by the method of: soaking the nerve graft for at least six hours in a solution comprising one or more sulfobetaines;washing the nerve graft in one or more solutions of a buffered salt;extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent; andwashing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the nerve graft is immunologically tolerated when implanted. 11. The cell-free neural tissue replacement of claim 10, further comprising the step of: adhering one or more components to the nerve graft before storing, wherein the components are selected from the group consisting of a cell, a polymer, a bioactive compound, and combinations thereof. 12. The cell-free neural tissue replacement of claim 11, wherein the cell is selected from the group consisting of bone, cartilage, dermal, muscular, thyroidal, parathyroidal, lymphoid, pancreatic, urinary, digestive, hepatic, biliary, vascular, nervous, reproductive and combinations thereof. 13. The cell-free neural tissue replacement of claim 11, wherein the cells are obtained from a donor, a host, from cell culture from a donor or a host, or cell cultures of established cells, tissue cells, or transformed cell lines. 14. The cell-free neural tissue replacement of claim 11, wherein the bioactive compound is selected from the group consisting of a drug, protein, peptide, polysaccharide, fatty acid, nucleic acid, oligonucleotide, detectable agent, organic molecules, inorganic molecules or salts and combinations thereof that include natural or synthetic analogs, derivatives, or mimetic versions of the bioactive compound for therapeutic, prophylactic and diagnostic purposes. 15. The cell-free neural tissue replacement of claim 11, wherein the polymer is selected from the group consisting of naturally occurring, synthetically-derived, covalently crosslinkable, ionically crosslinkable, hydrophilic, and combinations thereof. 16. The cell-free neural tissue replacement of claim 10, wherein the nerve graft is further modified into a structure selected from the group consisting of a suture, tube, sheet, film, scaffold, valve, limb replacement, tissue transplant, and joint for delivery into the body. 17. The cell-free neural tissue replacement of claim 10, wherein the step of washing the tissue replacement comprises serial solutions of a buffered salt comprises three serial washes of 100 mM sodium and 50 mM phosphate for about 15 minutes each. 18. The cell-free neural tissue replacement of claim 10, wherein the nerve graft is harvested from mammalian cadaver. 19. The cell-free neural tissue replacement of claim 18, wherein the nerve graft is cleaned of fat and blood after harvesting and rinsed for several hours in deionized distilled water. 20. An optimized acellular nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and is immunologically tolerated, wherein the nerve graft is made by the method of soaking the nerve graft for at least six hours in a solution comprising one or more sulfobetaines; washing the nerve graft in one or more solutions of a buffered salt;extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent; andwashing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the acellular neural graft, is immunologically tolerated when implanted. 21. The acellular graft of claim 20, further comprising the step of adhering one or more components to the neural graft before storing. 22. The acellular graft of claim 20, further comprising a component selected from the group consisting of a cell, a polymer, a bioactive compound or combinations thereof. 23. The acellular graft of claim 20, wherein the neural graft is stored at about 4 degrees centigrade in a sterile, buffered solution until use. 24. The method of claim 1, wherein the nerve graft is an autograft, allograft, or xenograft. 25. The acellular nerve graft of claim 20, wherein the nerve graft is an autograft, allograft, or xenograft. 26. A method for preparing a native, nerve cell-free tissue replacement nerve graft comprising the steps of: soaking the nerve graft for at least six hours in a solution comprising sulfobetaine;washing the nerve graft in one or more solutions of a buffered salt;extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent;washing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the nerve graft is immunologically tolerated when implanted; andadhering one or more components to the nerve graft before storing, wherein the components are selected from the group consisting of a cell, a polymer, a bioactive compound, and combinations thereof, wherein the cells are obtained from a donor, a host, from cell culture from a donor or a host, or cell cultures of established cells, tissue cells, or transformed cell lines.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (29)
Emil A. Tanagho ; Rajvir Dahiya ; Tom F. Lue ; Gerald R. Cunha, Acellular matrix grafts: preparation and use.
Livesey Stephen A. (Eltham TX AUX) del Campo Anthony A. (Houston TX) Nag Abhijit (Houston TX) Nichols Ken B. (The Woodlands TX) Coleman Christopher (Houston TX), Method for processing and preserving collagen-based tissues for transplantation.
Myles, Arthur; Ilsley, Stephen R.; Mannuzza, Frank J., Method of providing a substrate with a ready-to-use, uniformly distributed extracellular matrix.
Orgill Dennis P. ; Butler Charles E. ; Barlow Mark ; Ritterbush Scott ; Yannas Ioannis V. ; Compton Carolyn C., Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft.
Fishman Mark C. (Newton Centre MA) Igarashi Michihiro (Saitama JPX) Strittmatter Stephen M. (Clinton CT), Peptides to overcome inhibition of nerve growth.
Wolfinbarger, Jr., Lloyd; Lange, Perry; Linhurst, Alyce; Moore, Eric; Nolf, Barry, Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced.
Matsuda Takehisa,JPX ; Sugawara Takashi,JPX ; Inoue Kazuhiko,JPX, Substrate for controlling growth direction of nerve fibers and process for preparing the same, method for controlling g.
Bret A. Ferree, Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.